Pipelines in Development
- Developing antidiabetic and anti-obesity drug pipeline based on successful results in-vitro and in-vivo models
- This research was published in April 2021 in ‘Gastroenterology’, the top academic journal in the digestive field
- RSVI-301/302 are the main pipelines for diabetes and obesity.
- RSVI-301 will branch out to treatments for obesity, NAFLD, GI after the anti-diabetes pipeline's clinical trial phase 1
